Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
16.9.2021 15:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced SOS1::pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and LUMAKRAS™ (sotorasib), the first US Food and Drug Administration (FDA) approved KRASG12C inhibitor for adult patients with locally advanced or metastatic non-small cell lung cancer. The trial will investigate potential synergistic effects of this combination, possibly improving therapeutic outcomes beyond those of KRASG12C inhibitor therapy alone, specifically for people living with lung and colorectal cancers.
Preclinical data suggest that the combination of a KRASG12C inhibitor with a SOS1::pan-KRAS inhibitor may result in increased anti-tumor activity in KRAS G12C-driven cancers based on the complementary mechanisms of these targeted oncology agents.1 2 By shifting the equilibrium from active KRAS towards the inactive form, SOS1::pan-KRAS inhibitors have the potential to sensitize KRAS G12C-mutant tumors to covalent KRASG12C inhibitors that bind to inactive KRAS. In addition, SOS1 inhibitors block feedback reactivation which occurs upon pathway inhibition.
“We are excited to partner with Amgen, who have pioneered KRAS G12C inhibition, and to further expand our program to make a difference for people living with KRAS-driven cancers,” said Francesco Di Marco, Ph.D., Corporate Senior Vice President, Global Therapy Area Head Oncology at Boehringer Ingelheim. “Boehringer Ingelheim follows an ‘all-in’ research approach to taking cancer on, including the first and most advanced SOS1::pan-KRAS inhibitor which we investigate in several combinations and cancer types to realize even more opportunities to deliver potential therapeutic benefits to cancer patients.”
Under the terms of the non-exclusive collaboration, Amgen will be the sponsor of the trial and Boehringer Ingelheim and Amgen will jointly share the costs of and oversee clinical development for the combined therapy.
About BI 1701963
BI 1701963 is an investigational, orally available small molecule, that binds to the catalytic domain of SOS1 preventing the interaction with inactive KRAS. This reduces the formation of active KRAS and in consequence inhibits MAPK pathway signaling in KRAS-dependent cancers. SOS1 inhibition also simultaneously blocks feedback driven reactivation of the MAPK pathway. The selective inhibition of SOS1 is a therapeutic concept that could allow KRAS blockade irrespective of KRAS mutation type (pan-KRAS approach). SOS1::KRAS inhibitors exhibit activity on a broad spectrum of KRAS alleles, including all major G12D/V/C and G13D oncoproteins, as published by Hofmann MH, et al. in Cancer Discovery, a journal of the American Association of Cancer Research (AACR). BI 1701963 is currently being evaluated in phase I clinical trials in patients with advanced KRAS-mutated cancers to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of BI 1701963 alone and in combination with MEK inhibitors, KRASG12C inhibitors or irinotecan.
Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/clinical-collaboration-amgen
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005436/en/
Contact information
Media Contacts:
Boehringer Ingelheim
Sarah Soetbeer
Junior Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-183874
press@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna to Power Apple Upgrade, a New Hardware Leasing Program Offered by Apple28.7.2026 15:15:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, today announced it would be the leasing provider behind the Apple Upgrade program, a new hardware leasing option available from Apple in the United States. Lease Apple hardware for low monthly payments Provided by Klarna, Apple Upgrade offers customers a new way to pay for eligible iPhone, Mac, iPad and Apple Watch. Customers can select from 12- and 24-month leasing options for iPhone and Apple Watch, and 24- and 36-month leasing options for Mac and iPad. In addition, when customers first enroll in Apple Upgrade, they can trade in an existing device to further lower their monthly payments during their initial lease term. The freedom to upgrade, return, or buy When the lease ends, customers choose what suits them: upgrade to the latest model1, purchase their device, or return it. A seamless checkout, and easy to manage payments Apple and Klarna have built an easy and seamless checkout experience which shows customers exactl
Third-Party EPDs Confirm C-Crete Cement Cuts Embodied Carbon by up to 95% — and It’s Already Being Poured Commercially28.7.2026 15:05:00 EEST | Press release
C-Crete Technologies has published two Environmental Product Declarations (EPDs) verifying that its cements cut embodied carbon by up to 95% versus conventional portland cement. C-Crete’s technology converts a broad range of natural rocks and industrial by-products into cementitious binders with no clinker and no kiln, so production is inherently decentralized — and it is already being poured in commercial concrete today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728132467/en/ Representative C-Crete's project portfolio. More than 4000 tons of C-Crete's ultra-low carbon concrete have been poured in different cities since 2023. C-Crete's oldest pour is more than 3 years old, with no sign of degradation or cracking. Verified performance, not projections C-Crete’s clinker-free Ultra Low Carbon Cement (NRMCA EPD 20353) reports a global warming potential of just 43.1 kg CO2-eq per metric ton — roughly 95% below the 919 kg
Nine in 10 LPs More Likely to Commit to Funds Using Leverage When Disclosure is Clear28.7.2026 15:00:00 EEST | Press release
Fund-level leverage and liquidity tools have moved from specialist financing techniques to mainstream private capital infrastructure, according to new research from CSC, the leading provider of global business administration and compliance solutions. The findings show that limited partners (LPs) are increasingly open to the use of these tools when disclosure is clear, but general partners (GPs) face growing pressure to prove that the operating model behind them is controlled, transparent, and investor-ready. CSC¹ surveyed 300 GPs and 200 LPs across North America, Europe, the U.K., and Asia Pacific. The report, Future Private Capital CFO 2026: How CFOs are becoming the architects of operational trust, examines how fund finance, liquidity management, reporting, outsourcing, cybersecurity, and AI governance are reshaping the role of the private capital CFO. The findings show the market has moved beyond a simple debate about whether fund-level leverage should be used. Instead, LP focus is
Omilia Appoints David Ogden as VP of Revenue Operations28.7.2026 15:00:00 EEST | Press release
Omilia, a global leader in Self-Learning Agentic CX, today announced the appointment of Dave Ogden as Vice President of Revenue Operations. Ogden will be responsible for scaling Omilia’s global revenue operations function spanning sales operations, forecasting, and commercial execution as the company accelerates growth across its key markets. In this role, Ogden will design and operate the revenue infrastructure that connects sales, marketing, and customer success, including forecasting, pipeline management, and deal desk operations. He joins as Omilia expands its direct and partner-led go-to-market across the US, Europe, Latin America and Australia, and will play a central role in ensuring that growth scales in a disciplined, data-driven way. Ogden brings more than 15 years of enterprise SaaS revenue and commercial operations experience. He spent nine years at Five9, progressing through a series of senior roles including VP of Strategy, Planning and Growth, where he led the build-out
B-Secur and CSEM Partner to Bring Clinically-Validated Heart Monitoring to Health Wearables28.7.2026 15:00:00 EEST | Press release
CSEM, the Swiss-based technology innovation centre, and B-Secur, a leader in advanced biosensing technology, today announced a partnership to bring clinically-validated heart monitoring capability to health wearables. The collaboration pairs CSEM's 25+ years of leadership in PPG-based vital signs monitoring with B-Secur's multiple FDA-cleared ECG algorithms and analytics, offering device manufacturers and digital health companies a route to integrating more accurate, market-ready heart monitoring into their products — for applications including remote patient monitoring, cardiovascular health, and chronic disease management. “By combining CSEM’s expertise in photoplethysmography-based vital signs monitoring with B-Secur’s ECG analytics, we are enabling a new class of multimodal sensing solutions that deliver clinically relevant insights. This partnership reflects our commitment to translating cutting-edge sensing and algorithm technologies into real-world healthcare applications.” Jose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom